Brazil's health regulatory agency, Anvisa, has approved the export of cannabis-based medicinal products and active pharmaceutical ingredients produced in the country [1, 2].
This move signals a significant shift in Brazil's approach to the cannabis industry. By allowing domestic production for international markets, Brazil is positioning itself as a potential global supplier of pharmaceutical-grade cannabis derivatives.
The decision by Anvisa aligns the agency's regulations with a November 2024 ruling by the Superior Tribunal de Justiça [4]. That court decision recognized the legality of producing cannabis in Brazil, provided the activity is exclusively for medicinal and pharmaceutical purposes [4].
The new regulatory framework includes provisions for the types of products that can be shipped abroad. Specifically, formulations may contain more than 0.2% THC [2]. This allows Brazilian producers to create a wider range of medicinal products tailored to different international pharmaceutical standards.
There are conflicting reports regarding the exact date of the announcement. Some sources said the approval occurred on Wednesday the 6th [1], while other reports said Wednesday the 28th [3]. Despite the discrepancy in dates, the regulatory path forward remains clear.
The transition to these new rules will not be immediate. Anvisa said the regulations will take effect in six months [1]. This window provides Brazilian pharmaceutical companies and growers time to adjust their infrastructure and compliance protocols to meet export standards.
While some reports focus specifically on the export of finished products and active ingredients [1, 2], other accounts indicate the resolution also addresses the cultivation of the cannabis plant itself [3]. This comprehensive approach suggests a goal of creating a fully integrated domestic supply chain, from seed to export.
“Anvisa approved the export of cannabis-based medicinal products and active pharmaceutical ingredients produced in Brazil”
The alignment of Anvisa's regulations with the Superior Tribunal de Justiça's 2024 ruling removes a major legal hurdle for the Brazilian pharmaceutical industry. By permitting the export of high-THC products, Brazil is transitioning from a restrictive import-only model to a commercial production model, likely aiming to capture a share of the global medicinal cannabis market.
